May 2006
Volume 47, Issue 13
ARVO Annual Meeting Abstract  |   May 2006
Identification of a Potential Novel Anti–Angiogenic Mechanism in the Injury–Healing Cornea
Author Affiliations & Notes
  • R. Mohan
    University of Kentucky, Lexington, KY
    Ophthalmology and Visual Science,
    Pharmaceutical Sciences,
  • P. Bargagna–Mohan
    University of Kentucky, Lexington, KY
    Ophthalmology and Visual Science,
  • Footnotes
    Commercial Relationships  R. Mohan, patent application, P; P. Bargagna–Mohan, patent application, P.
  • Footnotes
    Support  Kentucky Science and Engineering Foundation, Fight for Sight Foundation, Research to Prevent Blindness Challenge Award
Investigative Ophthalmology & Visual Science May 2006, Vol.47, 3906. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      R. Mohan, P. Bargagna–Mohan; Identification of a Potential Novel Anti–Angiogenic Mechanism in the Injury–Healing Cornea . Invest. Ophthalmol. Vis. Sci. 2006;47(13):3906.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : Withaferin A (WA) is a potent small molecule inhibitor of angiogenesis and targets the ubiquitin proteasome pathway (UPP). In this study, we investigated the abundant corneal protein transketolase (TKT) as a potential downstream mediator of WA’s anti–angiogenic mechanism.

Methods: : Corneal angiogenesis was initiated in C57BL/6 mice in one eye by application of 0.15M sodium hydroxide followed by complete debridement of corneal and limbal epithelia. Injured mice in groups of 4 were treated daily with vehicle (DMSO) or WA by intraperiteoneal injection and, time–course and dose–response experiments were performed. Equal amounts of protein pooled from samples in each group were subjected to immunoblotting or Coomassie blue staining after fractionation on 4–20% SDS– polyacrylamide gels. Blots were probed with antibodies against ubiquitin, TKT and ß–actin. In other such experiments, whole eyes were isolated after 4 and 8 days post–injury. Frozen tissue sections were subjected to immunohistochemical analysis using anti–TKT antibody and detected with FITC–conjugated secondary antibodies. Whole corneal buttons were also isolated and stained with FITC–conjugated anti–CD–31 antibodies. Images were captured on a Leica confocal microscope.

Results: : We observed an increase in global ubiquitinated proteins in the injured corneas compared to control uninjured fellow eyes. WA treatment downregulates the levels of injury–induced ubiquitinated proteins in healing corneas. Intriguingly, the abundant 70 kDa TKT band was also found to be ubiquitinated and it becomes the most predominant ubiquitinated species in epithelium of vascularized corneas. This pattern of TKT ubiquitination increases in levels over time post–injury. The striking upregulation of TKT ubiquitination was downregulated by WA treatment in association with the inhibition of angiogenesis.

Conclusions: : WA exerts a novel mechanism of anti–angiogenesis by downregulating expression of ubiquitinated TKT in injured corneas. The characterization of TKT ubiquitinated isoform(s) and their role in corneal angiogenesis is currently under investigation.

Keywords: cornea: basic science • pharmacology • protein modifications-post translational 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.